New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Iovance Biotherapeutics, Inc.

Contributing Author

Recent Articles by Iovance Biotherapeutics, Inc.

Sep-19	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Aug-29	Iovance Biotherapeutics to Present at Upcoming Conferences IOVA GlobeNewswire
Aug-22	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Aug-18	Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma IOVA GlobeNewswire
Aug-07	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 IOVA GlobeNewswire
Jul-24	Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 IOVA GlobeNewswire
Jul-18	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Jul-15	Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer IOVA GlobeNewswire
Jul-14	Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi in Patients with Advanced Melanoma IOVA GlobeNewswire
Jul-10	Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy IOVA GlobeNewswire
Jun-23	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Jun-10	Iovance Biotherapeutics to Present at Upcoming Conference IOVA GlobeNewswire
Jun-02	The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi (lifileucel) in Patients with Advanced Melanoma IOVA GlobeNewswire
May-22	Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting IOVA GlobeNewswire
May-16	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
May-08	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 IOVA GlobeNewswire
May-02	Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 IOVA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.